Ontak denileukin diftitox: Phase II data; marketed to treat persistent or recurrent CTCL

In an ongoing U.S. Phase II trial, 9 of 10 patients had reductions in peripheral CLL cells after at least 3 courses of Ontak. Three patients had reductions of 99% or more, 6 of 10 had reductions in th...